



ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB

Equivalent of Form PTO/ISB/08A (04-07)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

~~44~~ Substitute for form 1449/PTO

**THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary.)

Sheet 1 of 1

<i>Complete if Known</i>	
Application Number	10/633,699
Filing Date	August 5, 2003
First Named Inventor	UMANA, Pablo
Art Unit	1633
Examiner Name	BURKHART, Michael D.
Attorney Docket Number	1975.001/0004/T1S/T-M/M-N

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ² Number ³ Kind Code ⁴ (if known)				
	FP1	EP 0 475 354 A2	03/18/1992	Behringwerke Aktiengesellschaft		ISR
	FP2	WO 98/06835 A2	02/19/1998	The Texas A & M University System		
	FP3	WO 99/54342 A1	10/28/1999	Umana <i>et al.</i>		
	FP4	WO 02/079255 A1	10/10/2002	Idec Pharmaceuticals Corporation		

821082_1.DOC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB

Examiner Signature	/Michael Burkhart/	Date Considered	01/30/2009
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate translation as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by § 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/633,699
				Filing Date	August 5, 2003
				First Named Inventor	UMANA, Pablo
				Art Unit	1633
				Examiner Name	BURKHART, Michael D.
Sheet	1	of	3	Attorney Docket Number	1975.0010004/TJS/T-M/M-N

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
	NPL1	Boyd, P.N., <i>et al.</i> , "The Effect of the Removal of Sialic Acid, Galactose and Total Carbohydrate on the Functional Activity of Campath-1H," <i>Molec. Immunol.</i> 32:1311-1318, Pergamon Press (1995)			
	NPL2	Davies, J. <i>et al.</i> , "Expression of GnTIII in a Recombinant Anti-CD20 Production Cell Line: Expression of Antibodies with Altered Glycoforms Leads to an Increase in ADCC Through Higher Affinity for FcγRIII," <i>Biotechnol. Bioeng.</i> 74:288-294, John Wiley & Sons, Inc. (August 2001)			
	NPL3	De Bree, R., <i>et al.</i> , "Clinical screening of monoclonal antibodies 323/A3, cSF-25 and K928 for suitability of targeting tumours in the upper aerodigestive and respiratory tract," <i>Nucl. Med. Commun.</i> 15:613-627, Lippincott, Williams & Wilkins (1994)			
	NPL4	Dürrbach, A., <i>et al.</i> , "Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma <i>in vitro</i> ," <i>Cancer Gene Ther.</i> 6:564-571, Nature Publishing Group (November-December 1999)			
	NPL5	Fukuta, K., <i>et al.</i> , "Control of Bisecting GlcNAc Addition to N-Linked Sugar Chains," <i>J. Biol. Chem.</i> 275:23456-23461, The American Society for Biochemistry and Molecular Biology, Inc. (August 2000)			
	NPL6	Kaszubowski, P.A., <i>et al.</i> , "A Cytotoxic Monoclonal Antibody to Colon Adenocarcinoma," <i>Cancer Res.</i> 44:1194-1197, American Association for Cancer Research (1984)			
	NPL7	Luiten, R.M., <i>et al.</i> , "Chimeric immunoglobulin E reactive with tumor-associated antigen activates human FcεRI bearing cells," <i>Hum. Antibodies</i> 8:169-180, IOS Press (December 1997)			
	NPL8	Lund, J., "Multiple Interactions of IgG with Its Core Oligosaccharide Can Modulate Recognition by Complement and Human Fcγ Receptor I and Influence the Synthesis of Its Oligosaccharide Chains," <i>J. Immunol.</i> 157:4963-4969, The American Association of Immunologists (1996)			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

Examiner Signature	/Michael Burkhart/	Date Considered	01/30/2009
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant or inventor designation may be omitted. ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to be had by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/633,699
				Filing Date	August 5, 2003
				First Named Inventor	UMANA, Pablo
				Art Unit	1633
				Examiner Name	BURKHART, Michael D.
				Attorney Docket Number	1975.0010004/TJS/T-M/M-N
Sheet	2	of	3		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published			T ³
	NPL9	Murakami, H., et al., "Human-Human Hybridomas Secreting Antibodies Specific to Human Lung Carcinoma," <i>In Vitro Cell. Develop. Biol.</i> 21:593-596, Tissue Culture Association, Inc. (1985)			
	NPL10	Raju, T.S., et al., "Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics," <i>Glycobiol.</i> 10: 477-486, IRL Press at Oxford University Press (May 2000)			
	NPL11	Sheng, Y., et al., "Remodeling of Glycoconjugates on CD44 Enhances Cell Adhesion to Hyaluronan, Tumor Growth and Metastasis in B16 Melanoma Cells Expressing β 1, 4-N-Acetylglucosaminyltransferase III," <i>Int. J. Cancer</i> 73:850-858, Wiley-Liss, Inc. (December 1997)			
	NPL12	Umaña, P., et al., "Tetracycline-Regulated Overexpression of Glycosyltransferases in Chinese Hamster Ovary Cells," <i>Biotechnol. Bioeng.</i> 65:542-549, John Wiley & Sons, Inc. (December 1999)			
	NPL13	Valone, F.H., et al., "Phase Ia/Ib Trial of Bispecific Antibody MDX-210 in Patients with Advanced Breast or Ovarian Cancer That Overexpresses the Proto-Oncogene HER-2/neu," <i>J. Clin. Oncol.</i> 13:2281-2292, American Society for Clinical Oncology (1995)			
	NPL14	Copy of Supplementary European Search Report for European Application No. 99 91 8731, mailed December 17, 2004, European Patent Office, The Hague			
	NPL15	Copy of Office Action for co-pending United States Patent Application No. 10/633,697, Umana et al., filed August 5, 2003, mailed on April 11, 2006			
	NPL16	Copy of Office Action for co-pending United States Patent Application No. 10/633,697, Umana et al., filed August 5, 2003, mailed on September 10, 2007			
	NPL17	Copy of Office Action for co-pending United States Patent Application No. 10/633,697, Umana et al., filed August 5, 2003, mailed on January 10, 2008			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

Examiner Signature	/Michael Burkhardt/	Date Considered	01/30/2009
--------------------	---------------------	-----------------	------------

*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. ³Information collection requirement is required by 37 CFR 1.95. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application for a patent. The burden is estimated to be 122 hours per response. This collection is estimated to be complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

Equivalent of Form PTO/SB/08B (04-07)

Approved for use through 09/30/2007 OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<i>Complete if Known</i>	
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/633,699
			Filing Date	August 5, 2003
			First Named Inventor	UMANA, Pablo
			Art Unit	1633
			Examiner Name	BURKHART, Michael D.
Sheet	3	of	3	Attorney Docket Number
				1975.0010004/TJS/T-M/M-N
	NPL18	Copy of Office Action for co-pending United States Patent Application No. 10/437,388, Umana <i>et al.</i> , filed May 14, 2003, mailed on October 26, 2006		
	NPL19	Copy of Office Action for co-pending United States Patent Application No. 10/437,388, Umana <i>et al.</i> , filed May 14, 2003, mailed on July 25, 2007		
	NPL20	Copy of Office Action for co-pending United States Patent Application No. 10/437,388, Umana <i>et al.</i> , filed May 14, 2003, mailed on January 24, 2008		

821083_1.DOC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

Examiner Signature	/Michael Burkhart/	Date Considered	01/30/2009
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's reference designation number (optional) *Applicant is to place a check mark here if English language Translation is attached. The collection of information is required by 37 CFR 1.96. The information is being collected by the public without a pre-existing file (and by the USPTO to process) an application. Confidentiality is guaranteed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.